In order to assess if neuregulin-induced pErbB3 activation occurs also in the clinical setting we decided to carry out a clinical study in BRAF mutated melanoma patients undergoing standard dual therapy with MAPK inhibitors. The gene discussed is BRAF; the disease is melanoma.